South Korea · Delayed Price · Currency is KRW Kukje Pharma Statistics
Total Valuation
Kukje Pharma has a market cap or net worth of KRW 72.80 billion. The enterprise value is 94.35 billion.
| Market Cap | 72.80B |
| Enterprise Value | 94.35B |
Important Dates
The last earnings date was Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | Mar 12, 2026 |
Share Statistics
Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 1.09% in one year.
| Current Share Class | 20.36M |
| Shares Outstanding | 20.36M |
| Shares Change (YoY) | +1.09% |
| Shares Change (QoQ) | +3.00% |
| Owned by Insiders (%) | 12.92% |
| Owned by Institutions (%) | 1.96% |
| Float | 12.66M |
Valuation Ratios
The trailing PE ratio is 12.26.
| PE Ratio | 12.26 |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 24.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.34, with an EV/FCF ratio of -101.22.
| EV / Earnings | 15.74 |
| EV / Sales | 0.53 |
| EV / EBITDA | 10.34 |
| EV / EBIT | 16.13 |
| EV / FCF | -101.22 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.09 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 3.39 |
| Debt / FCF | -33.17 |
| Interest Coverage | 6.87 |
Financial Efficiency
Return on equity (ROE) is 6.33% and return on invested capital (ROIC) is 4.32%.
| Return on Equity (ROE) | 6.33% |
| Return on Assets (ROA) | 2.13% |
| Return on Invested Capital (ROIC) | 4.32% |
| Return on Capital Employed (ROCE) | 4.89% |
| Weighted Average Cost of Capital (WACC) | 5.26% |
| Revenue Per Employee | 717.63M |
| Profits Per Employee | 24.16M |
| Employee Count | 248 |
| Asset Turnover | 1.04 |
| Inventory Turnover | 3.73 |
Taxes
In the past 12 months, Kukje Pharma has paid 839.88 million in taxes.
| Income Tax | 839.88M |
| Effective Tax Rate | 12.29% |
Stock Price Statistics
The stock price has decreased by -27.04% in the last 52 weeks. The beta is 0.40, so Kukje Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -27.04% |
| 50-Day Moving Average | 4,563.00 |
| 200-Day Moving Average | 4,519.65 |
| Relative Strength Index (RSI) | 20.45 |
| Average Volume (20 Days) | 147,752 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kukje Pharma had revenue of KRW 177.97 billion and earned 5.99 billion in profits. Earnings per share was 291.49.
| Revenue | 177.97B |
| Gross Profit | 95.08B |
| Operating Income | 5.85B |
| Pretax Income | 6.83B |
| Net Income | 5.99B |
| EBITDA | 9.13B |
| EBIT | 5.85B |
| Earnings Per Share (EPS) | 291.49 |
Balance Sheet
The company has 9.38 billion in cash and 30.92 billion in debt, with a net cash position of -21.54 billion or -1,057.97 per share.
| Cash & Cash Equivalents | 9.38B |
| Total Debt | 30.92B |
| Net Cash | -21.54B |
| Net Cash Per Share | -1,057.97 |
| Equity (Book Value) | 98.50B |
| Book Value Per Share | 4,676.10 |
| Working Capital | 5.51B |
Cash Flow
In the last 12 months, operating cash flow was 2.93 billion and capital expenditures -3.86 billion, giving a free cash flow of -932.07 million.
| Operating Cash Flow | 2.93B |
| Capital Expenditures | -3.86B |
| Depreciation & Amortization | 3.28B |
| Net Borrowing | 811.97M |
| Free Cash Flow | -932.07M |
| FCF Per Share | -45.77 |
Margins
Gross margin is 53.42%, with operating and profit margins of 3.29% and 3.37%.
| Gross Margin | 53.42% |
| Operating Margin | 3.29% |
| Pretax Margin | 3.84% |
| Profit Margin | 3.37% |
| EBITDA Margin | 5.13% |
| EBIT Margin | 3.29% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.84%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.84% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 5 |
| Payout Ratio | 10.19% |
| Buyback Yield | -1.09% |
| Shareholder Yield | -0.26% |
| Earnings Yield | 8.23% |
| FCF Yield | -1.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 17, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Kukje Pharma has an Altman Z-Score of 1.93 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.93 |
| Piotroski F-Score | 5 |